Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Currently, tirzepatide is the clear choice for type 2 diabetes because it has FDA approval for this indication and extensive clinical evidence
Because retatrutide simultaneously targets GIP, GLP-1, and glucagon receptors, the authors suggest that studying these combined signaling pathways may help expand scientific understanding of how metabolic and neurological systems interact in preclinical models
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD/NASH) Nature Medicine (2024) A substudy of the Phase 2 obesity trial, published in Nature Medicine, examined retatrutide's effects in participants with metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD)
[DOI] [PubMed] [Google Scholar] 144.Nicolau J., Tamayo M.I., Sanchis P., Pujol A., Perez-Bec G., Sfondrini G., Masmiquel L
For once-weekly GLP-1 medications, changing the time of day may not materially affect gastrointestinal symptoms
If you havent already, be sure to check out CardioNerds episode #350 where we discuss the basics and mechanism of action of GLP-1 RAs with Dr
